Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Moderna (MRNA) ended the recent trading session at $31.25, demonstrating a -2.95% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.01%. Elsewhere, the Dow ...

Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its ...

Leerink Partners analyst Mani Foroohar maintained a Sell rating on Moderna on June 30. The company’s shares closed yesterday at $28.69. Foroohar covers the Healthcare sector, focusing on stocks such ...

Future Outlook and Challenges As Moderna looks to the future, several factors will be critical in determining its success.

Moderna has pulled the filing for FDA approval of its flu/COVID combination vaccine. The biotech plans to resubmit later this year with the phase 3 flu vaccine efficacy data the agency wants to see.

Why Vaccine-Maker Moderna Is Injecting AI Across the Company More than 3,000 GPTs are reportedly in use at Moderna, which has partnered with OpenAI.

Moderna's cancer vaccine shows promise, but the company faces challenges with declining COVID demand and slow RSV uptake.